Bpost SA NV (13B)

Summer months typically are not the season for OTC ticker spikes...I, as well, hope for a spike as twice this year already and given the tiny market cap NXGB could...but we know also that the CEO never addresses the reason and limits for the dilution which leave the taste that she will continue

Our burgeoning EVLI fire breathing dragon 🐉 hasn’t even begun its oncoming summer fun, but it’s coming real soon 🚀 

🔥 This is exactly the type of strategic initiative investors look for.
A venture platform powered by proprietary AI, supported by acquisition expertise, and backed by an established growth strategy creates a differentiated approach to building long-term shareholder value as Nocera Hol

Big deal TD.. the president has many charges against him and judgements as well .   The last time I look . Mr. Trump is doing quite well.
So yu have no point in what u saying.

INTU - thanks for excellent reply.

I guess here's some observations from my own work (engineering/science field) that I think are relevant. In my work, yes, the AI can be wrong, but it's not about the AI being only right 90% of the time and that being an issue. It's about the fact tha

Stellar (XLM)'s Quantum Plan: Preparing for Post-Quantum Threats
Jun 09, 2026
https://blockchain.news/news/stellar-quantum-preparedness-plan

I'M TRYING TO READ ALL FILINGS FROM YOU SEND US A LINKS FROM 2024 AND NOW 2026 , BY NOW PPS SHOULD BE AROUND .10 CENTS ... DO YOU AGREE ? OR ALL THE NEWS IS PLAIN FLUFF ?

.005

Over Under Sideways Down · The Yardbirds ( Jeff Beck )

https://www.youtube.com/watch?v=1CYaCoQlGuA

Watch and learn like always! Nobody gets meetings with major airlines if they’ve got nothing to offer of consequence 🔥 

Didn’t the bank case say Natario was a director at Hiru?

NO. Neither the bank nor any of the filings ever claimed that. In fact, Hiru's own defense counsel argued in their court submissions that the actions were carried out by "unrelated parties."

Your attempt at creati

Yu Wong TD!!! Again yu not know what is going on with revere securities... If it's to unload stock ... Alpine takes care of that.
There is much more to revere than yu think I bet

I am thinking of submitting my resume to Anavex for the CEO position...how does this opening to my cover letter sound?

"I am confident that my lack of experience in biotech makes me more qualified than your previous CEO"

A few things to look at before referencing the Space-x IPO with Delfin's situation:

1. Space-x has had pre-IPO revenue ($14B in '23 and almost $20B last year). Anything Delfin brought in is leveraged towards future operations.
2. Space-x has employee stock options - incentive

I know... There is always 1 somewhere. Too emotional to be playing down here in the dark basement.

Oops. I was wrong about this play. Sorry.
No support. Lots of selling into bids.
Stock has no strength when the Q's are weak.

BS again. Study Revolution Medicine for how successful pre-venue biotechs behave. NWBO is a dilution scam where excuses, victim mindset, and blame games are a norm.

I feel sorry for anyone that invested 12-13 years ago and started following your BS commentary. They will never come clo

HKIT, there it goes

$PSRU Multiple lines of business development coming to fruition in 2026 and future years.

2025 Annual Net Profit of $1.5M+ increasing with 2026 Q1 Net Profit of $448.5K.

No need for a reverse split as no need for dilution for over 8 months.

Overview here:

If the story is so great, then who would be swelling at $0.0025? Ask yourself that question.
I have answered it over and over here.
Buyer beware. JMO.

rick - Big Deal. Do they sell Beaver Nuggets ? Deer Corn ? Live Bait ?

Buckees Rules.

Exactamundo NewBreed, and they’ve laid it all out for us as to what’s coming next 🚀 

Judging from all the "proof" and length of your post, you haven't made much here. Good try though. 
But you and your alter ego George sure know how to manipulate stocks together...

Any life here in the otc for THIS COMPANY?

By the way ...
Unicycive Therapeutics (UNCY) is legally permitted to negotiate a standalone commercialization deal with DaVita, unless they choose to sign a strictly "exclusive, all-inclusive" U.S. license with CSL Vifor.

In the renal and dialysis pharmaceutical market, biotech